Pharma & Healthcare
Global 9-valent Human Papillomavirus Vaccine Market Research Report 2025
- Jul 08, 25
- ID: 355935
- Pages: 82
- Figures: 80
- Views: 31
The global market for 9-valent Human Papillomavirus Vaccine was valued at US$ 5076 million in the year 2024 and is projected to reach a revised size of US$ 9581 million by 2031, growing at a CAGR of 9.5% during the forecast period.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on 9-valent Human Papillomavirus Vaccine competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
The 9-valent human papillomavirus (HPV) vaccine is a recombinant vaccine that protects against nine HPV types: 6, 11, 16, 18, 31, 33, 45, 52, and 58. These types are associated with over 90% of cervical cancers and the majority of other HPV-related anogenital and oropharyngeal cancers. The vaccine is made using virus-like particle (VLP) technology and is administered in 2- or 3-dose schedules, depending on age. It is the most comprehensive HPV vaccine to date and plays a key role in cervical cancer prevention programs worldwide.
North American market for 9-valent Human Papillomavirus Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for 9-valent Human Papillomavirus Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of 9-valent Human Papillomavirus Vaccine include Merck Group, GSK, Wantai Biological Pharmacy, Zhifei Biological Products, Walvax Biotechnology, Beijing Health Guard Biotechnology, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for 9-valent Human Papillomavirus Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding 9-valent Human Papillomavirus Vaccine.
The 9-valent Human Papillomavirus Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global 9-valent Human Papillomavirus Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the 9-valent Human Papillomavirus Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Merck Group
GSK
Wantai Biological Pharmacy
Zhifei Biological Products
Walvax Biotechnology
Beijing Health Guard Biotechnology
Segment by Type
HPV6
HPV11
HPV16
HPV18
Others
Segment by Application
Hospital
Health Center
Epidemic Prevention Station
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of 9-valent Human Papillomavirus Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of 9-valent Human Papillomavirus Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on 9-valent Human Papillomavirus Vaccine competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
The 9-valent human papillomavirus (HPV) vaccine is a recombinant vaccine that protects against nine HPV types: 6, 11, 16, 18, 31, 33, 45, 52, and 58. These types are associated with over 90% of cervical cancers and the majority of other HPV-related anogenital and oropharyngeal cancers. The vaccine is made using virus-like particle (VLP) technology and is administered in 2- or 3-dose schedules, depending on age. It is the most comprehensive HPV vaccine to date and plays a key role in cervical cancer prevention programs worldwide.
North American market for 9-valent Human Papillomavirus Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for 9-valent Human Papillomavirus Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of 9-valent Human Papillomavirus Vaccine include Merck Group, GSK, Wantai Biological Pharmacy, Zhifei Biological Products, Walvax Biotechnology, Beijing Health Guard Biotechnology, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for 9-valent Human Papillomavirus Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding 9-valent Human Papillomavirus Vaccine.
The 9-valent Human Papillomavirus Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global 9-valent Human Papillomavirus Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the 9-valent Human Papillomavirus Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Merck Group
GSK
Wantai Biological Pharmacy
Zhifei Biological Products
Walvax Biotechnology
Beijing Health Guard Biotechnology
Segment by Type
HPV6
HPV11
HPV16
HPV18
Others
Segment by Application
Hospital
Health Center
Epidemic Prevention Station
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of 9-valent Human Papillomavirus Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of 9-valent Human Papillomavirus Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 9-valent Human Papillomavirus Vaccine Market Overview
1.1 Product Definition
1.2 9-valent Human Papillomavirus Vaccine by Type
1.2.1 Global 9-valent Human Papillomavirus Vaccine Market Value Comparison by Type (2024 VS 2031)
1.2.2 HPV6
1.2.3 HPV11
1.2.4 HPV16
1.2.5 HPV18
1.2.6 Others
1.3 9-valent Human Papillomavirus Vaccine by Application
1.3.1 Global 9-valent Human Papillomavirus Vaccine Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Health Center
1.3.4 Epidemic Prevention Station
1.3.5 Others
1.4 Global 9-valent Human Papillomavirus Vaccine Market Size Estimates and Forecasts
1.4.1 Global 9-valent Human Papillomavirus Vaccine Revenue 2020-2031
1.4.2 Global 9-valent Human Papillomavirus Vaccine Sales 2020-2031
1.4.3 Global 9-valent Human Papillomavirus Vaccine Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 9-valent Human Papillomavirus Vaccine Market Competition by Manufacturers
2.1 Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Manufacturers (2020-2025)
2.2 Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Manufacturers (2020-2025)
2.3 Global 9-valent Human Papillomavirus Vaccine Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of 9-valent Human Papillomavirus Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of 9-valent Human Papillomavirus Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of 9-valent Human Papillomavirus Vaccine, Product Type & Application
2.7 Global Key Manufacturers of 9-valent Human Papillomavirus Vaccine, Date of Enter into This Industry
2.8 Global 9-valent Human Papillomavirus Vaccine Market Competitive Situation and Trends
2.8.1 Global 9-valent Human Papillomavirus Vaccine Market Concentration Rate
2.8.2 The Global 5 and 10 Largest 9-valent Human Papillomavirus Vaccine Players Market Share by Revenue
2.8.3 Global 9-valent Human Papillomavirus Vaccine Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global 9-valent Human Papillomavirus Vaccine Market Scenario by Region
3.1 Global 9-valent Human Papillomavirus Vaccine Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global 9-valent Human Papillomavirus Vaccine Sales by Region: 2020-2031
3.2.1 Global 9-valent Human Papillomavirus Vaccine Sales by Region: 2020-2025
3.2.2 Global 9-valent Human Papillomavirus Vaccine Sales by Region: 2026-2031
3.3 Global 9-valent Human Papillomavirus Vaccine Revenue by Region: 2020-2031
3.3.1 Global 9-valent Human Papillomavirus Vaccine Revenue by Region: 2020-2025
3.3.2 Global 9-valent Human Papillomavirus Vaccine Revenue by Region: 2026-2031
3.4 North America 9-valent Human Papillomavirus Vaccine Market Facts & Figures by Country
3.4.1 North America 9-valent Human Papillomavirus Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America 9-valent Human Papillomavirus Vaccine Sales by Country (2020-2031)
3.4.3 North America 9-valent Human Papillomavirus Vaccine Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe 9-valent Human Papillomavirus Vaccine Market Facts & Figures by Country
3.5.1 Europe 9-valent Human Papillomavirus Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe 9-valent Human Papillomavirus Vaccine Sales by Country (2020-2031)
3.5.3 Europe 9-valent Human Papillomavirus Vaccine Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific 9-valent Human Papillomavirus Vaccine Market Facts & Figures by Region
3.6.1 Asia Pacific 9-valent Human Papillomavirus Vaccine Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific 9-valent Human Papillomavirus Vaccine Sales by Region (2020-2031)
3.6.3 Asia Pacific 9-valent Human Papillomavirus Vaccine Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America 9-valent Human Papillomavirus Vaccine Market Facts & Figures by Country
3.7.1 Latin America 9-valent Human Papillomavirus Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America 9-valent Human Papillomavirus Vaccine Sales by Country (2020-2031)
3.7.3 Latin America 9-valent Human Papillomavirus Vaccine Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa 9-valent Human Papillomavirus Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa 9-valent Human Papillomavirus Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales by Country (2020-2031)
3.8.3 Middle East and Africa 9-valent Human Papillomavirus Vaccine Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global 9-valent Human Papillomavirus Vaccine Sales by Type (2020-2031)
4.1.1 Global 9-valent Human Papillomavirus Vaccine Sales by Type (2020-2025)
4.1.2 Global 9-valent Human Papillomavirus Vaccine Sales by Type (2026-2031)
4.1.3 Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Type (2020-2031)
4.2 Global 9-valent Human Papillomavirus Vaccine Revenue by Type (2020-2031)
4.2.1 Global 9-valent Human Papillomavirus Vaccine Revenue by Type (2020-2025)
4.2.2 Global 9-valent Human Papillomavirus Vaccine Revenue by Type (2026-2031)
4.2.3 Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Type (2020-2031)
4.3 Global 9-valent Human Papillomavirus Vaccine Price by Type (2020-2031)
5 Segment by Application
5.1 Global 9-valent Human Papillomavirus Vaccine Sales by Application (2020-2031)
5.1.1 Global 9-valent Human Papillomavirus Vaccine Sales by Application (2020-2025)
5.1.2 Global 9-valent Human Papillomavirus Vaccine Sales by Application (2026-2031)
5.1.3 Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Application (2020-2031)
5.2 Global 9-valent Human Papillomavirus Vaccine Revenue by Application (2020-2031)
5.2.1 Global 9-valent Human Papillomavirus Vaccine Revenue by Application (2020-2025)
5.2.2 Global 9-valent Human Papillomavirus Vaccine Revenue by Application (2026-2031)
5.2.3 Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Application (2020-2031)
5.3 Global 9-valent Human Papillomavirus Vaccine Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Merck Group
6.1.1 Merck Group Company Information
6.1.2 Merck Group Description and Business Overview
6.1.3 Merck Group 9-valent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Merck Group 9-valent Human Papillomavirus Vaccine Product Portfolio
6.1.5 Merck Group Recent Developments/Updates
6.2 GSK
6.2.1 GSK Company Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK 9-valent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.2.4 GSK 9-valent Human Papillomavirus Vaccine Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Wantai Biological Pharmacy
6.3.1 Wantai Biological Pharmacy Company Information
6.3.2 Wantai Biological Pharmacy Description and Business Overview
6.3.3 Wantai Biological Pharmacy 9-valent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Wantai Biological Pharmacy 9-valent Human Papillomavirus Vaccine Product Portfolio
6.3.5 Wantai Biological Pharmacy Recent Developments/Updates
6.4 Zhifei Biological Products
6.4.1 Zhifei Biological Products Company Information
6.4.2 Zhifei Biological Products Description and Business Overview
6.4.3 Zhifei Biological Products 9-valent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Zhifei Biological Products 9-valent Human Papillomavirus Vaccine Product Portfolio
6.4.5 Zhifei Biological Products Recent Developments/Updates
6.5 Walvax Biotechnology
6.5.1 Walvax Biotechnology Company Information
6.5.2 Walvax Biotechnology Description and Business Overview
6.5.3 Walvax Biotechnology 9-valent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Walvax Biotechnology 9-valent Human Papillomavirus Vaccine Product Portfolio
6.5.5 Walvax Biotechnology Recent Developments/Updates
6.6 Beijing Health Guard Biotechnology
6.6.1 Beijing Health Guard Biotechnology Company Information
6.6.2 Beijing Health Guard Biotechnology Description and Business Overview
6.6.3 Beijing Health Guard Biotechnology 9-valent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Beijing Health Guard Biotechnology 9-valent Human Papillomavirus Vaccine Product Portfolio
6.6.5 Beijing Health Guard Biotechnology Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 9-valent Human Papillomavirus Vaccine Industry Chain Analysis
7.2 9-valent Human Papillomavirus Vaccine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 9-valent Human Papillomavirus Vaccine Production Mode & Process Analysis
7.4 9-valent Human Papillomavirus Vaccine Sales and Marketing
7.4.1 9-valent Human Papillomavirus Vaccine Sales Channels
7.4.2 9-valent Human Papillomavirus Vaccine Distributors
7.5 9-valent Human Papillomavirus Vaccine Customer Analysis
8 9-valent Human Papillomavirus Vaccine Market Dynamics
8.1 9-valent Human Papillomavirus Vaccine Industry Trends
8.2 9-valent Human Papillomavirus Vaccine Market Drivers
8.3 9-valent Human Papillomavirus Vaccine Market Challenges
8.4 9-valent Human Papillomavirus Vaccine Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 9-valent Human Papillomavirus Vaccine by Type
1.2.1 Global 9-valent Human Papillomavirus Vaccine Market Value Comparison by Type (2024 VS 2031)
1.2.2 HPV6
1.2.3 HPV11
1.2.4 HPV16
1.2.5 HPV18
1.2.6 Others
1.3 9-valent Human Papillomavirus Vaccine by Application
1.3.1 Global 9-valent Human Papillomavirus Vaccine Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Health Center
1.3.4 Epidemic Prevention Station
1.3.5 Others
1.4 Global 9-valent Human Papillomavirus Vaccine Market Size Estimates and Forecasts
1.4.1 Global 9-valent Human Papillomavirus Vaccine Revenue 2020-2031
1.4.2 Global 9-valent Human Papillomavirus Vaccine Sales 2020-2031
1.4.3 Global 9-valent Human Papillomavirus Vaccine Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 9-valent Human Papillomavirus Vaccine Market Competition by Manufacturers
2.1 Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Manufacturers (2020-2025)
2.2 Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Manufacturers (2020-2025)
2.3 Global 9-valent Human Papillomavirus Vaccine Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of 9-valent Human Papillomavirus Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of 9-valent Human Papillomavirus Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of 9-valent Human Papillomavirus Vaccine, Product Type & Application
2.7 Global Key Manufacturers of 9-valent Human Papillomavirus Vaccine, Date of Enter into This Industry
2.8 Global 9-valent Human Papillomavirus Vaccine Market Competitive Situation and Trends
2.8.1 Global 9-valent Human Papillomavirus Vaccine Market Concentration Rate
2.8.2 The Global 5 and 10 Largest 9-valent Human Papillomavirus Vaccine Players Market Share by Revenue
2.8.3 Global 9-valent Human Papillomavirus Vaccine Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global 9-valent Human Papillomavirus Vaccine Market Scenario by Region
3.1 Global 9-valent Human Papillomavirus Vaccine Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global 9-valent Human Papillomavirus Vaccine Sales by Region: 2020-2031
3.2.1 Global 9-valent Human Papillomavirus Vaccine Sales by Region: 2020-2025
3.2.2 Global 9-valent Human Papillomavirus Vaccine Sales by Region: 2026-2031
3.3 Global 9-valent Human Papillomavirus Vaccine Revenue by Region: 2020-2031
3.3.1 Global 9-valent Human Papillomavirus Vaccine Revenue by Region: 2020-2025
3.3.2 Global 9-valent Human Papillomavirus Vaccine Revenue by Region: 2026-2031
3.4 North America 9-valent Human Papillomavirus Vaccine Market Facts & Figures by Country
3.4.1 North America 9-valent Human Papillomavirus Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America 9-valent Human Papillomavirus Vaccine Sales by Country (2020-2031)
3.4.3 North America 9-valent Human Papillomavirus Vaccine Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe 9-valent Human Papillomavirus Vaccine Market Facts & Figures by Country
3.5.1 Europe 9-valent Human Papillomavirus Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe 9-valent Human Papillomavirus Vaccine Sales by Country (2020-2031)
3.5.3 Europe 9-valent Human Papillomavirus Vaccine Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific 9-valent Human Papillomavirus Vaccine Market Facts & Figures by Region
3.6.1 Asia Pacific 9-valent Human Papillomavirus Vaccine Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific 9-valent Human Papillomavirus Vaccine Sales by Region (2020-2031)
3.6.3 Asia Pacific 9-valent Human Papillomavirus Vaccine Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America 9-valent Human Papillomavirus Vaccine Market Facts & Figures by Country
3.7.1 Latin America 9-valent Human Papillomavirus Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America 9-valent Human Papillomavirus Vaccine Sales by Country (2020-2031)
3.7.3 Latin America 9-valent Human Papillomavirus Vaccine Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa 9-valent Human Papillomavirus Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa 9-valent Human Papillomavirus Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales by Country (2020-2031)
3.8.3 Middle East and Africa 9-valent Human Papillomavirus Vaccine Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global 9-valent Human Papillomavirus Vaccine Sales by Type (2020-2031)
4.1.1 Global 9-valent Human Papillomavirus Vaccine Sales by Type (2020-2025)
4.1.2 Global 9-valent Human Papillomavirus Vaccine Sales by Type (2026-2031)
4.1.3 Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Type (2020-2031)
4.2 Global 9-valent Human Papillomavirus Vaccine Revenue by Type (2020-2031)
4.2.1 Global 9-valent Human Papillomavirus Vaccine Revenue by Type (2020-2025)
4.2.2 Global 9-valent Human Papillomavirus Vaccine Revenue by Type (2026-2031)
4.2.3 Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Type (2020-2031)
4.3 Global 9-valent Human Papillomavirus Vaccine Price by Type (2020-2031)
5 Segment by Application
5.1 Global 9-valent Human Papillomavirus Vaccine Sales by Application (2020-2031)
5.1.1 Global 9-valent Human Papillomavirus Vaccine Sales by Application (2020-2025)
5.1.2 Global 9-valent Human Papillomavirus Vaccine Sales by Application (2026-2031)
5.1.3 Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Application (2020-2031)
5.2 Global 9-valent Human Papillomavirus Vaccine Revenue by Application (2020-2031)
5.2.1 Global 9-valent Human Papillomavirus Vaccine Revenue by Application (2020-2025)
5.2.2 Global 9-valent Human Papillomavirus Vaccine Revenue by Application (2026-2031)
5.2.3 Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Application (2020-2031)
5.3 Global 9-valent Human Papillomavirus Vaccine Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Merck Group
6.1.1 Merck Group Company Information
6.1.2 Merck Group Description and Business Overview
6.1.3 Merck Group 9-valent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Merck Group 9-valent Human Papillomavirus Vaccine Product Portfolio
6.1.5 Merck Group Recent Developments/Updates
6.2 GSK
6.2.1 GSK Company Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK 9-valent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.2.4 GSK 9-valent Human Papillomavirus Vaccine Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Wantai Biological Pharmacy
6.3.1 Wantai Biological Pharmacy Company Information
6.3.2 Wantai Biological Pharmacy Description and Business Overview
6.3.3 Wantai Biological Pharmacy 9-valent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Wantai Biological Pharmacy 9-valent Human Papillomavirus Vaccine Product Portfolio
6.3.5 Wantai Biological Pharmacy Recent Developments/Updates
6.4 Zhifei Biological Products
6.4.1 Zhifei Biological Products Company Information
6.4.2 Zhifei Biological Products Description and Business Overview
6.4.3 Zhifei Biological Products 9-valent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Zhifei Biological Products 9-valent Human Papillomavirus Vaccine Product Portfolio
6.4.5 Zhifei Biological Products Recent Developments/Updates
6.5 Walvax Biotechnology
6.5.1 Walvax Biotechnology Company Information
6.5.2 Walvax Biotechnology Description and Business Overview
6.5.3 Walvax Biotechnology 9-valent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Walvax Biotechnology 9-valent Human Papillomavirus Vaccine Product Portfolio
6.5.5 Walvax Biotechnology Recent Developments/Updates
6.6 Beijing Health Guard Biotechnology
6.6.1 Beijing Health Guard Biotechnology Company Information
6.6.2 Beijing Health Guard Biotechnology Description and Business Overview
6.6.3 Beijing Health Guard Biotechnology 9-valent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Beijing Health Guard Biotechnology 9-valent Human Papillomavirus Vaccine Product Portfolio
6.6.5 Beijing Health Guard Biotechnology Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 9-valent Human Papillomavirus Vaccine Industry Chain Analysis
7.2 9-valent Human Papillomavirus Vaccine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 9-valent Human Papillomavirus Vaccine Production Mode & Process Analysis
7.4 9-valent Human Papillomavirus Vaccine Sales and Marketing
7.4.1 9-valent Human Papillomavirus Vaccine Sales Channels
7.4.2 9-valent Human Papillomavirus Vaccine Distributors
7.5 9-valent Human Papillomavirus Vaccine Customer Analysis
8 9-valent Human Papillomavirus Vaccine Market Dynamics
8.1 9-valent Human Papillomavirus Vaccine Industry Trends
8.2 9-valent Human Papillomavirus Vaccine Market Drivers
8.3 9-valent Human Papillomavirus Vaccine Market Challenges
8.4 9-valent Human Papillomavirus Vaccine Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global 9-valent Human Papillomavirus Vaccine Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global 9-valent Human Papillomavirus Vaccine Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global 9-valent Human Papillomavirus Vaccine Market Competitive Situation by Manufacturers in 2024
Table 4. Global 9-valent Human Papillomavirus Vaccine Sales (K Dose) of Key Manufacturers (2020-2025)
Table 5. Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Manufacturers (2020-2025)
Table 6. Global 9-valent Human Papillomavirus Vaccine Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global 9-valent Human Papillomavirus Vaccine Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market 9-valent Human Papillomavirus Vaccine Average Price (US$/Dose) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of 9-valent Human Papillomavirus Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of 9-valent Human Papillomavirus Vaccine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of 9-valent Human Papillomavirus Vaccine, Product Type & Application
Table 12. Global Key Manufacturers of 9-valent Human Papillomavirus Vaccine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global 9-valent Human Papillomavirus Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in 9-valent Human Papillomavirus Vaccine as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global 9-valent Human Papillomavirus Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global 9-valent Human Papillomavirus Vaccine Sales by Region (2020-2025) & (K Dose)
Table 18. Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Region (2020-2025)
Table 19. Global 9-valent Human Papillomavirus Vaccine Sales by Region (2026-2031) & (K Dose)
Table 20. Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Region (2026-2031)
Table 21. Global 9-valent Human Papillomavirus Vaccine Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Region (2020-2025)
Table 23. Global 9-valent Human Papillomavirus Vaccine Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Region (2026-2031)
Table 25. North America 9-valent Human Papillomavirus Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America 9-valent Human Papillomavirus Vaccine Sales by Country (2020-2025) & (K Dose)
Table 27. North America 9-valent Human Papillomavirus Vaccine Sales by Country (2026-2031) & (K Dose)
Table 28. North America 9-valent Human Papillomavirus Vaccine Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America 9-valent Human Papillomavirus Vaccine Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe 9-valent Human Papillomavirus Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe 9-valent Human Papillomavirus Vaccine Sales by Country (2020-2025) & (K Dose)
Table 32. Europe 9-valent Human Papillomavirus Vaccine Sales by Country (2026-2031) & (K Dose)
Table 33. Europe 9-valent Human Papillomavirus Vaccine Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe 9-valent Human Papillomavirus Vaccine Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific 9-valent Human Papillomavirus Vaccine Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific 9-valent Human Papillomavirus Vaccine Sales by Region (2020-2025) & (K Dose)
Table 37. Asia Pacific 9-valent Human Papillomavirus Vaccine Sales by Region (2026-2031) & (K Dose)
Table 38. Asia Pacific 9-valent Human Papillomavirus Vaccine Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific 9-valent Human Papillomavirus Vaccine Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America 9-valent Human Papillomavirus Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America 9-valent Human Papillomavirus Vaccine Sales by Country (2020-2025) & (K Dose)
Table 42. Latin America 9-valent Human Papillomavirus Vaccine Sales by Country (2026-2031) & (K Dose)
Table 43. Latin America 9-valent Human Papillomavirus Vaccine Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America 9-valent Human Papillomavirus Vaccine Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa 9-valent Human Papillomavirus Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales by Country (2020-2025) & (K Dose)
Table 47. Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales by Country (2026-2031) & (K Dose)
Table 48. Middle East and Africa 9-valent Human Papillomavirus Vaccine Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa 9-valent Human Papillomavirus Vaccine Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global 9-valent Human Papillomavirus Vaccine Sales (K Dose) by Type (2020-2025)
Table 51. Global 9-valent Human Papillomavirus Vaccine Sales (K Dose) by Type (2026-2031)
Table 52. Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Type (2020-2025)
Table 53. Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Type (2026-2031)
Table 54. Global 9-valent Human Papillomavirus Vaccine Revenue (US$ Million) by Type (2020-2025)
Table 55. Global 9-valent Human Papillomavirus Vaccine Revenue (US$ Million) by Type (2026-2031)
Table 56. Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Type (2020-2025)
Table 57. Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Type (2026-2031)
Table 58. Global 9-valent Human Papillomavirus Vaccine Price (US$/Dose) by Type (2020-2025)
Table 59. Global 9-valent Human Papillomavirus Vaccine Price (US$/Dose) by Type (2026-2031)
Table 60. Global 9-valent Human Papillomavirus Vaccine Sales (K Dose) by Application (2020-2025)
Table 61. Global 9-valent Human Papillomavirus Vaccine Sales (K Dose) by Application (2026-2031)
Table 62. Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Application (2020-2025)
Table 63. Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Application (2026-2031)
Table 64. Global 9-valent Human Papillomavirus Vaccine Revenue (US$ Million) by Application (2020-2025)
Table 65. Global 9-valent Human Papillomavirus Vaccine Revenue (US$ Million) by Application (2026-2031)
Table 66. Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Application (2020-2025)
Table 67. Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Application (2026-2031)
Table 68. Global 9-valent Human Papillomavirus Vaccine Price (US$/Dose) by Application (2020-2025)
Table 69. Global 9-valent Human Papillomavirus Vaccine Price (US$/Dose) by Application (2026-2031)
Table 70. Merck Group Company Information
Table 71. Merck Group Description and Business Overview
Table 72. Merck Group 9-valent Human Papillomavirus Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 73. Merck Group 9-valent Human Papillomavirus Vaccine Product
Table 74. Merck Group Recent Developments/Updates
Table 75. GSK Company Information
Table 76. GSK Description and Business Overview
Table 77. GSK 9-valent Human Papillomavirus Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 78. GSK 9-valent Human Papillomavirus Vaccine Product
Table 79. GSK Recent Developments/Updates
Table 80. Wantai Biological Pharmacy Company Information
Table 81. Wantai Biological Pharmacy Description and Business Overview
Table 82. Wantai Biological Pharmacy 9-valent Human Papillomavirus Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 83. Wantai Biological Pharmacy 9-valent Human Papillomavirus Vaccine Product
Table 84. Wantai Biological Pharmacy Recent Developments/Updates
Table 85. Zhifei Biological Products Company Information
Table 86. Zhifei Biological Products Description and Business Overview
Table 87. Zhifei Biological Products 9-valent Human Papillomavirus Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 88. Zhifei Biological Products 9-valent Human Papillomavirus Vaccine Product
Table 89. Zhifei Biological Products Recent Developments/Updates
Table 90. Walvax Biotechnology Company Information
Table 91. Walvax Biotechnology Description and Business Overview
Table 92. Walvax Biotechnology 9-valent Human Papillomavirus Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 93. Walvax Biotechnology 9-valent Human Papillomavirus Vaccine Product
Table 94. Walvax Biotechnology Recent Developments/Updates
Table 95. Beijing Health Guard Biotechnology Company Information
Table 96. Beijing Health Guard Biotechnology Description and Business Overview
Table 97. Beijing Health Guard Biotechnology 9-valent Human Papillomavirus Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 98. Beijing Health Guard Biotechnology 9-valent Human Papillomavirus Vaccine Product
Table 99. Beijing Health Guard Biotechnology Recent Developments/Updates
Table 100. Key Raw Materials Lists
Table 101. Raw Materials Key Suppliers Lists
Table 102. 9-valent Human Papillomavirus Vaccine Distributors List
Table 103. 9-valent Human Papillomavirus Vaccine Customers List
Table 104. 9-valent Human Papillomavirus Vaccine Market Trends
Table 105. 9-valent Human Papillomavirus Vaccine Market Drivers
Table 106. 9-valent Human Papillomavirus Vaccine Market Challenges
Table 107. 9-valent Human Papillomavirus Vaccine Market Restraints
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
Table 111. Authors List of This Report
List of Figures
Figure 1. Product Picture of 9-valent Human Papillomavirus Vaccine
Figure 2. Global 9-valent Human Papillomavirus Vaccine Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global 9-valent Human Papillomavirus Vaccine Market Share by Type: 2024 & 2031
Figure 4. HPV6 Product Picture
Figure 5. HPV11 Product Picture
Figure 6. HPV16 Product Picture
Figure 7. HPV18 Product Picture
Figure 8. Others Product Picture
Figure 9. Global 9-valent Human Papillomavirus Vaccine Market Value by Application (2020-2031) & (US$ Million)
Figure 10. Global 9-valent Human Papillomavirus Vaccine Market Share by Application: 2024 & 2031
Figure 11. Hospital
Figure 12. Health Center
Figure 13. Epidemic Prevention Station
Figure 14. Others
Figure 15. Global 9-valent Human Papillomavirus Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global 9-valent Human Papillomavirus Vaccine Market Size (2020-2031) & (US$ Million)
Figure 17. Global 9-valent Human Papillomavirus Vaccine Sales (2020-2031) & (K Dose)
Figure 18. Global 9-valent Human Papillomavirus Vaccine Average Price (US$/Dose) & (2020-2031)
Figure 19. 9-valent Human Papillomavirus Vaccine Report Years Considered
Figure 20. 9-valent Human Papillomavirus Vaccine Sales Share by Manufacturers in 2024
Figure 21. Global 9-valent Human Papillomavirus Vaccine Revenue Share by Manufacturers in 2024
Figure 22. Global 5 and 10 Largest 9-valent Human Papillomavirus Vaccine Players: Market Share by Revenue in 9-valent Human Papillomavirus Vaccine in 2024
Figure 23. 9-valent Human Papillomavirus Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 24. Global 9-valent Human Papillomavirus Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 25. North America 9-valent Human Papillomavirus Vaccine Sales Market Share by Country (2020-2031)
Figure 26. North America 9-valent Human Papillomavirus Vaccine Revenue Market Share by Country (2020-2031)
Figure 27. United States 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. Canada 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. Europe 9-valent Human Papillomavirus Vaccine Sales Market Share by Country (2020-2031)
Figure 30. Europe 9-valent Human Papillomavirus Vaccine Revenue Market Share by Country (2020-2031)
Figure 31. Germany 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. France 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. U.K. 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Italy 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Russia 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Asia Pacific 9-valent Human Papillomavirus Vaccine Sales Market Share by Region (2020-2031)
Figure 37. Asia Pacific 9-valent Human Papillomavirus Vaccine Revenue Market Share by Region (2020-2031)
Figure 38. China 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Japan 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. South Korea 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. India 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Australia 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. China Taiwan 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Southeast Asia 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Latin America 9-valent Human Papillomavirus Vaccine Sales Market Share by Country (2020-2031)
Figure 46. Latin America 9-valent Human Papillomavirus Vaccine Revenue Market Share by Country (2020-2031)
Figure 47. Mexico 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Brazil 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Argentina 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Colombia 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales Market Share by Country (2020-2031)
Figure 52. Middle East and Africa 9-valent Human Papillomavirus Vaccine Revenue Market Share by Country (2020-2031)
Figure 53. Turkey 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. Saudi Arabia 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. UAE 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 56. Global Sales Market Share of 9-valent Human Papillomavirus Vaccine by Type (2020-2031)
Figure 57. Global Revenue Market Share of 9-valent Human Papillomavirus Vaccine by Type (2020-2031)
Figure 58. Global 9-valent Human Papillomavirus Vaccine Price (US$/Dose) by Type (2020-2031)
Figure 59. Global Sales Market Share of 9-valent Human Papillomavirus Vaccine by Application (2020-2031)
Figure 60. Global Revenue Market Share of 9-valent Human Papillomavirus Vaccine by Application (2020-2031)
Figure 61. Global 9-valent Human Papillomavirus Vaccine Price (US$/Dose) by Application (2020-2031)
Figure 62. 9-valent Human Papillomavirus Vaccine Value Chain
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Table 1. Global 9-valent Human Papillomavirus Vaccine Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global 9-valent Human Papillomavirus Vaccine Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global 9-valent Human Papillomavirus Vaccine Market Competitive Situation by Manufacturers in 2024
Table 4. Global 9-valent Human Papillomavirus Vaccine Sales (K Dose) of Key Manufacturers (2020-2025)
Table 5. Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Manufacturers (2020-2025)
Table 6. Global 9-valent Human Papillomavirus Vaccine Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global 9-valent Human Papillomavirus Vaccine Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market 9-valent Human Papillomavirus Vaccine Average Price (US$/Dose) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of 9-valent Human Papillomavirus Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of 9-valent Human Papillomavirus Vaccine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of 9-valent Human Papillomavirus Vaccine, Product Type & Application
Table 12. Global Key Manufacturers of 9-valent Human Papillomavirus Vaccine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global 9-valent Human Papillomavirus Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in 9-valent Human Papillomavirus Vaccine as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global 9-valent Human Papillomavirus Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global 9-valent Human Papillomavirus Vaccine Sales by Region (2020-2025) & (K Dose)
Table 18. Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Region (2020-2025)
Table 19. Global 9-valent Human Papillomavirus Vaccine Sales by Region (2026-2031) & (K Dose)
Table 20. Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Region (2026-2031)
Table 21. Global 9-valent Human Papillomavirus Vaccine Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Region (2020-2025)
Table 23. Global 9-valent Human Papillomavirus Vaccine Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Region (2026-2031)
Table 25. North America 9-valent Human Papillomavirus Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America 9-valent Human Papillomavirus Vaccine Sales by Country (2020-2025) & (K Dose)
Table 27. North America 9-valent Human Papillomavirus Vaccine Sales by Country (2026-2031) & (K Dose)
Table 28. North America 9-valent Human Papillomavirus Vaccine Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America 9-valent Human Papillomavirus Vaccine Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe 9-valent Human Papillomavirus Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe 9-valent Human Papillomavirus Vaccine Sales by Country (2020-2025) & (K Dose)
Table 32. Europe 9-valent Human Papillomavirus Vaccine Sales by Country (2026-2031) & (K Dose)
Table 33. Europe 9-valent Human Papillomavirus Vaccine Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe 9-valent Human Papillomavirus Vaccine Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific 9-valent Human Papillomavirus Vaccine Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific 9-valent Human Papillomavirus Vaccine Sales by Region (2020-2025) & (K Dose)
Table 37. Asia Pacific 9-valent Human Papillomavirus Vaccine Sales by Region (2026-2031) & (K Dose)
Table 38. Asia Pacific 9-valent Human Papillomavirus Vaccine Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific 9-valent Human Papillomavirus Vaccine Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America 9-valent Human Papillomavirus Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America 9-valent Human Papillomavirus Vaccine Sales by Country (2020-2025) & (K Dose)
Table 42. Latin America 9-valent Human Papillomavirus Vaccine Sales by Country (2026-2031) & (K Dose)
Table 43. Latin America 9-valent Human Papillomavirus Vaccine Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America 9-valent Human Papillomavirus Vaccine Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa 9-valent Human Papillomavirus Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales by Country (2020-2025) & (K Dose)
Table 47. Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales by Country (2026-2031) & (K Dose)
Table 48. Middle East and Africa 9-valent Human Papillomavirus Vaccine Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa 9-valent Human Papillomavirus Vaccine Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global 9-valent Human Papillomavirus Vaccine Sales (K Dose) by Type (2020-2025)
Table 51. Global 9-valent Human Papillomavirus Vaccine Sales (K Dose) by Type (2026-2031)
Table 52. Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Type (2020-2025)
Table 53. Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Type (2026-2031)
Table 54. Global 9-valent Human Papillomavirus Vaccine Revenue (US$ Million) by Type (2020-2025)
Table 55. Global 9-valent Human Papillomavirus Vaccine Revenue (US$ Million) by Type (2026-2031)
Table 56. Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Type (2020-2025)
Table 57. Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Type (2026-2031)
Table 58. Global 9-valent Human Papillomavirus Vaccine Price (US$/Dose) by Type (2020-2025)
Table 59. Global 9-valent Human Papillomavirus Vaccine Price (US$/Dose) by Type (2026-2031)
Table 60. Global 9-valent Human Papillomavirus Vaccine Sales (K Dose) by Application (2020-2025)
Table 61. Global 9-valent Human Papillomavirus Vaccine Sales (K Dose) by Application (2026-2031)
Table 62. Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Application (2020-2025)
Table 63. Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Application (2026-2031)
Table 64. Global 9-valent Human Papillomavirus Vaccine Revenue (US$ Million) by Application (2020-2025)
Table 65. Global 9-valent Human Papillomavirus Vaccine Revenue (US$ Million) by Application (2026-2031)
Table 66. Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Application (2020-2025)
Table 67. Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Application (2026-2031)
Table 68. Global 9-valent Human Papillomavirus Vaccine Price (US$/Dose) by Application (2020-2025)
Table 69. Global 9-valent Human Papillomavirus Vaccine Price (US$/Dose) by Application (2026-2031)
Table 70. Merck Group Company Information
Table 71. Merck Group Description and Business Overview
Table 72. Merck Group 9-valent Human Papillomavirus Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 73. Merck Group 9-valent Human Papillomavirus Vaccine Product
Table 74. Merck Group Recent Developments/Updates
Table 75. GSK Company Information
Table 76. GSK Description and Business Overview
Table 77. GSK 9-valent Human Papillomavirus Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 78. GSK 9-valent Human Papillomavirus Vaccine Product
Table 79. GSK Recent Developments/Updates
Table 80. Wantai Biological Pharmacy Company Information
Table 81. Wantai Biological Pharmacy Description and Business Overview
Table 82. Wantai Biological Pharmacy 9-valent Human Papillomavirus Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 83. Wantai Biological Pharmacy 9-valent Human Papillomavirus Vaccine Product
Table 84. Wantai Biological Pharmacy Recent Developments/Updates
Table 85. Zhifei Biological Products Company Information
Table 86. Zhifei Biological Products Description and Business Overview
Table 87. Zhifei Biological Products 9-valent Human Papillomavirus Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 88. Zhifei Biological Products 9-valent Human Papillomavirus Vaccine Product
Table 89. Zhifei Biological Products Recent Developments/Updates
Table 90. Walvax Biotechnology Company Information
Table 91. Walvax Biotechnology Description and Business Overview
Table 92. Walvax Biotechnology 9-valent Human Papillomavirus Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 93. Walvax Biotechnology 9-valent Human Papillomavirus Vaccine Product
Table 94. Walvax Biotechnology Recent Developments/Updates
Table 95. Beijing Health Guard Biotechnology Company Information
Table 96. Beijing Health Guard Biotechnology Description and Business Overview
Table 97. Beijing Health Guard Biotechnology 9-valent Human Papillomavirus Vaccine Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 98. Beijing Health Guard Biotechnology 9-valent Human Papillomavirus Vaccine Product
Table 99. Beijing Health Guard Biotechnology Recent Developments/Updates
Table 100. Key Raw Materials Lists
Table 101. Raw Materials Key Suppliers Lists
Table 102. 9-valent Human Papillomavirus Vaccine Distributors List
Table 103. 9-valent Human Papillomavirus Vaccine Customers List
Table 104. 9-valent Human Papillomavirus Vaccine Market Trends
Table 105. 9-valent Human Papillomavirus Vaccine Market Drivers
Table 106. 9-valent Human Papillomavirus Vaccine Market Challenges
Table 107. 9-valent Human Papillomavirus Vaccine Market Restraints
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
Table 111. Authors List of This Report
List of Figures
Figure 1. Product Picture of 9-valent Human Papillomavirus Vaccine
Figure 2. Global 9-valent Human Papillomavirus Vaccine Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global 9-valent Human Papillomavirus Vaccine Market Share by Type: 2024 & 2031
Figure 4. HPV6 Product Picture
Figure 5. HPV11 Product Picture
Figure 6. HPV16 Product Picture
Figure 7. HPV18 Product Picture
Figure 8. Others Product Picture
Figure 9. Global 9-valent Human Papillomavirus Vaccine Market Value by Application (2020-2031) & (US$ Million)
Figure 10. Global 9-valent Human Papillomavirus Vaccine Market Share by Application: 2024 & 2031
Figure 11. Hospital
Figure 12. Health Center
Figure 13. Epidemic Prevention Station
Figure 14. Others
Figure 15. Global 9-valent Human Papillomavirus Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global 9-valent Human Papillomavirus Vaccine Market Size (2020-2031) & (US$ Million)
Figure 17. Global 9-valent Human Papillomavirus Vaccine Sales (2020-2031) & (K Dose)
Figure 18. Global 9-valent Human Papillomavirus Vaccine Average Price (US$/Dose) & (2020-2031)
Figure 19. 9-valent Human Papillomavirus Vaccine Report Years Considered
Figure 20. 9-valent Human Papillomavirus Vaccine Sales Share by Manufacturers in 2024
Figure 21. Global 9-valent Human Papillomavirus Vaccine Revenue Share by Manufacturers in 2024
Figure 22. Global 5 and 10 Largest 9-valent Human Papillomavirus Vaccine Players: Market Share by Revenue in 9-valent Human Papillomavirus Vaccine in 2024
Figure 23. 9-valent Human Papillomavirus Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 24. Global 9-valent Human Papillomavirus Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 25. North America 9-valent Human Papillomavirus Vaccine Sales Market Share by Country (2020-2031)
Figure 26. North America 9-valent Human Papillomavirus Vaccine Revenue Market Share by Country (2020-2031)
Figure 27. United States 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 28. Canada 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. Europe 9-valent Human Papillomavirus Vaccine Sales Market Share by Country (2020-2031)
Figure 30. Europe 9-valent Human Papillomavirus Vaccine Revenue Market Share by Country (2020-2031)
Figure 31. Germany 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. France 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. U.K. 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 34. Italy 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 35. Russia 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Asia Pacific 9-valent Human Papillomavirus Vaccine Sales Market Share by Region (2020-2031)
Figure 37. Asia Pacific 9-valent Human Papillomavirus Vaccine Revenue Market Share by Region (2020-2031)
Figure 38. China 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Japan 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. South Korea 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. India 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Australia 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. China Taiwan 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Southeast Asia 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Latin America 9-valent Human Papillomavirus Vaccine Sales Market Share by Country (2020-2031)
Figure 46. Latin America 9-valent Human Papillomavirus Vaccine Revenue Market Share by Country (2020-2031)
Figure 47. Mexico 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Brazil 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Argentina 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Colombia 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales Market Share by Country (2020-2031)
Figure 52. Middle East and Africa 9-valent Human Papillomavirus Vaccine Revenue Market Share by Country (2020-2031)
Figure 53. Turkey 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. Saudi Arabia 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 55. UAE 9-valent Human Papillomavirus Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 56. Global Sales Market Share of 9-valent Human Papillomavirus Vaccine by Type (2020-2031)
Figure 57. Global Revenue Market Share of 9-valent Human Papillomavirus Vaccine by Type (2020-2031)
Figure 58. Global 9-valent Human Papillomavirus Vaccine Price (US$/Dose) by Type (2020-2031)
Figure 59. Global Sales Market Share of 9-valent Human Papillomavirus Vaccine by Application (2020-2031)
Figure 60. Global Revenue Market Share of 9-valent Human Papillomavirus Vaccine by Application (2020-2031)
Figure 61. Global 9-valent Human Papillomavirus Vaccine Price (US$/Dose) by Application (2020-2031)
Figure 62. 9-valent Human Papillomavirus Vaccine Value Chain
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Trichosanthes Kirilowii Extract Market Research Report 2026
Feb 24, 26
Global Glass Lined Containers Market Research Report 2026
Feb 24, 26
Global Open End Wrenches Market Research Report 2026
Feb 24, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232